Hologic

As of December 5, 2017, Hologic operates in the field of creating and supplying technologies for healthcare.

The history of the company since 1960.

Activity indicators

2018: Losses of $111.3 million, revenue - $3.2 billion

In fiscal 2018, Hologic's revenue amounted to $3.2 billion against $3.1 billion a year earlier. The reporting 12-month period ended on September 29, 2018.

The American manufacturer of mammographic and radiological equipment earned $2.6 billion on the sale of equipment and other products, while in 2017 these revenues were measured at $2.5 billion. Hologic's annual revenue from services and other sources of cash inflows rose from $520.8 million to $574 million.

Hologic Revenue Dynamics

We ended the year clearly with a stronger position than we started, as we improved underlying growth in the largest divisions of Breast Health and Molecular Diagnostics. In addition, international sales continue to show steady growth, and we have completed two attractive acquisitions that spurred Breast Health's business growth, "said Steve MacMillan, President, CEO and Chairman of the Hologic Board of Directors.

Hologic sales outside the United States in 2018 financial year amounted to $634 million, which is 13% higher than a year ago. The growth rate of international business is increasing. In 2017, revenue abroad increased by 11%, and in 2016 there was a decline at all.

In the segment of diagnostic equipment, foreign revenue accounts for 23% of sales. In mammographic and surgical equipment segments, the values ​ ​ are measured at 22% and 16%, respectively.

In 2018, the financial year for the sale of Hologic diagnostic solutions turned out to be $1.1 billion, which corresponds to 35.7% in total revenue. The share of mammographic products amounted to 37.9%, and their sales - $1.2 billion.

The fiscal year 2018 turned out to be unprofitable for Hologic: monetary losses reached $111.3 million. According to the results of the previous reporting year, the company received a net profit of $755.5 million.^[1]

History

2021

Purchase of the developer of diagnostic systems Mobidiag for $795 million

In early April 2021, Hologic acquired the developer of diagnostic systems Mobidiag for $795 million. The company did not disclose the detailed parameters of the transaction. More details here.

Purchase of Test Designer for Molecular Diagnosis of Breast Cancer Biotheranostics

In early January 2021, Hologic announced the acquisition of Biotheranostics for $230 million. The deal is expected to close in February 2021. Its detailed conditions are not disclosed. More details here.

Purchase of breast biopsy technology developer Somatex Medical Technologies

In early January 2021, Hologic acquired Somatex Medical Technologies, which specializes in biopsy site markers and localization technologies. The acquisition is estimated at about $64 million and includes the Somatex Tumark tissue marker line, in respect of which Hologic has already acted as a distributor in the United States. More details here.

2020: Acessa Health Myoma Treatment Developer Purchase

At the end of August 2020, Hologic announced its acquisition Acessa Health, a myoma treatment company, worth about $80 million. The Acessa ProVu system shall supplement the products MyoSure Hologic for hysteroscopic removal uterine myoma. More details here.

2019: Purchase of the manufacturer of ultrasound devices SuperSonic Imagine for $85 million

At the end of June 2019, Hologic announced the acquisition of the manufacturer Ultrasound sets SuperSonic Imagine for $85 million. More. here

2018: Purchase of oncosurgical device developer Focus Therapeutics

On September 27, 2018, Hologic signed an agreement to acquire Focus Therapeutics, a developer of oncosurgical devices, for $125 million. The deal will be closed in early October. More details here.